IMAC (IMAC) Competitors $0.04 +0.00 (+8.11%) As of 04/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. XWEL, MNDR, NUWE, OGEN, SXTP, RSLS, CANF, SNES, ACON, and TIVCShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include XWELL (XWEL), Mobile-health Network Solutions (MNDR), Nuwellis (NUWE), Oragenics (OGEN), 60 Degrees Pharmaceuticals (SXTP), ReShape Lifesciences (RSLS), Can-Fite BioPharma (CANF), SenesTech (SNES), Aclarion (ACON), and Tivic Health Systems (TIVC). These companies are all part of the "medical" sector. IMAC vs. XWELL Mobile-health Network Solutions Nuwellis Oragenics 60 Degrees Pharmaceuticals ReShape Lifesciences Can-Fite BioPharma SenesTech Aclarion Tivic Health Systems XWELL (NASDAQ:XWEL) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media refer more to XWEL or IMAC? In the previous week, IMAC had 1 more articles in the media than XWELL. MarketBeat recorded 3 mentions for IMAC and 2 mentions for XWELL. XWELL's average media sentiment score of 0.96 beat IMAC's score of -0.16 indicating that XWELL is being referred to more favorably in the media. Company Overall Sentiment XWELL Positive IMAC Neutral Is XWEL or IMAC more profitable? XWELL has a net margin of -46.82% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat XWELL's return on equity.Company Net Margins Return on Equity Return on Assets XWELL-46.82% -88.27% -43.24% IMAC -75.40%-52.17%-34.51% Which has preferable valuation and earnings, XWEL or IMAC? IMAC has lower revenue, but higher earnings than XWELL. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXWELL$33.90M0.12-$27.74M-$3.62-0.21IMAC$15.22M0.07-$10.54MN/AN/A Does the MarketBeat Community believe in XWEL or IMAC? IMAC received 68 more outperform votes than XWELL when rated by MarketBeat users. However, 75.00% of users gave XWELL an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformXWELLOutperform Votes375.00% Underperform Votes125.00% IMACOutperform Votes7160.17% Underperform Votes4739.83% Do institutionals and insiders have more ownership in XWEL or IMAC? 8.7% of XWELL shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 8.8% of XWELL shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, XWEL or IMAC? XWELL has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. SummaryIMAC beats XWELL on 7 of the 13 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.06M$932,000.00$5.57B$7.83BDividend YieldN/AN/A5.11%4.22%P/E RatioN/AN/A22.4418.48Price / Sales0.070.07394.09103.59Price / CashN/AN/A38.1834.62Price / Book0.060.066.774.25Net Income-$10.54M-$10.54M$3.22B$248.23M7 Day PerformanceN/AN/A1.49%0.89%1 Month PerformanceN/AN/A4.00%3.53%1 Year PerformanceN/AN/A16.21%5.08% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.04+8.1%N/A-98.9%$1.06M$15.22M0.00106Gap UpXWELXWELL1.2404 of 5 stars$0.80+2.7%N/A-57.2%$4.20M$33.90M-0.22360Short Interest ↓MNDRMobile-health Network SolutionsN/A$1.44+0.7%N/A-99.2%$4.16M$13.97M0.00N/ANews CoverageNegative NewsGap DownNUWENuwellis3.0495 of 5 stars$0.95-5.0%$17.00+1,689.5%-81.7%$4.16M$8.74M-0.0170Short Interest ↓Gap DownOGENOragenicsN/A$0.19-2.7%N/A-82.0%$4.12M$40,000.00-0.035Analyst ForecastNews CoverageNegative NewsSXTP60 Degrees Pharmaceuticals0.4734 of 5 stars$2.79-5.4%N/A+133.2%$4.11M$607,574.00-0.283RSLSReShape Lifesciences0.4501 of 5 stars$0.36-0.8%N/A-96.5%$4.08M$8.01M-0.0350Short Interest ↑Negative NewsGap UpCANFCan-Fite BioPharma1.6584 of 5 stars$1.15+1.8%$14.00+1,117.4%-47.3%$4.07M$674,000.00-0.648Gap UpSNESSenesTech2.7706 of 5 stars$2.27flat$10.00+340.5%-70.4%$4.03M$1.86M-0.2330Upcoming EarningsShort Interest ↓Gap DownACONAclarion1.5023 of 5 stars$6.84-8.9%$11,758.50+171,807.9%-99.8%$3.98M$45,724.000.007Short Interest ↑News CoverageTIVCTivic Health Systems0.1762 of 5 stars$6.47-9.1%N/A-75.3%$3.97M$780,000.000.0010Short Interest ↑Gap Down Related Companies and Tools Related Companies XWELL Competitors Mobile-health Network Solutions Competitors Nuwellis Competitors Oragenics Competitors 60 Degrees Pharmaceuticals Competitors ReShape Lifesciences Competitors Can-Fite BioPharma Competitors SenesTech Competitors Aclarion Competitors Tivic Health Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.